This report was first published by Endpoints News. To see the original version, click here
Backlash is brewing against a sweeping overhaul of Germany’s health insurance system as Eli Lilly and Boehringer Ingelheim slash investment in the country.
The drugmakers’ cuts come after the German government proposed various measures to save more than €60 billion ($69 billion) in healthcare costs, including reducing spending on drugs. The changes are set to become law this summer.
您已阅读12%（474字），剩余88%（3623字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。